Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2025 | $60.00 → $99.00 | In-line → Outperform | Evercore ISI |
| 2/12/2025 | $35.00 | Sell → Hold | TD Cowen |
| 2/3/2025 | $65.00 | Buy | H.C. Wainwright |
| 8/6/2024 | $88.00 → $84.00 | Buy | Needham |
| 8/2/2024 | $90.00 | Buy | Rodman & Renshaw |
| 6/28/2024 | Neutral | Guggenheim | |
| 2/15/2024 | Peer Perform | Wolfe Research | |
| 12/11/2023 | $30.00 | Market Perform → Underperform | TD Cowen |
ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, has been named to the fifth annual TIME 100 Most Influential Companies list. The Company was recognized in the Pioneers category for its groundbreaking work in advancing the field of gene editing. TIME highlighted CRISPR Therapeutics' expansion beyond its landmark success in treating sickle cell disease and beta thalassemia, noting the Company's progress into diseases with significant unmet medical need such as cardiovascular and autoimmune diseases. This momentum reflects CRISPR Therape
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile- -Complete Phase 1 data presentation for CTX310 anticipated at a medical meeting in the second half of 2025- -Data update for CTX320™, targeting the LPA gene, now expected in the first half of 2026- -Preclinical in vivo cardiovascular program CTX340™ advancing toward IND / CTA filings targeting refractory hypertension- ZUG, Switzerland and BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company fo
ZUG, Switzerland and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. William Blair's 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 11:20 a.m. CT Goldman Sachs' 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 3:20 p.m. ET A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events.
8-K - CRISPR Therapeutics AG (0001674416) (Filer)
8-K - CRISPR Therapeutics AG (0001674416) (Filer)
424B5 - CRISPR Therapeutics AG (0001674416) (Filer)
3/A - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
Evercore ISI upgraded CRISPR Therapeutics from In-line to Outperform and set a new price target of $99.00 from $60.00 previously
TD Cowen upgraded CRISPR Therapeutics from Sell to Hold and set a new price target of $35.00
H.C. Wainwright initiated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $65.00
ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company's annual general meeting to be held this year. "We are excited to welcome Briggs to our Board of Directors," said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics. "His extensive experience in the pharmaceutical industry and expertise in clinical development will be a tremendous asset as we continue to advance our innovative platform and pip
-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Company al
ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. He joins CRISPR Therapeutics from William Blair & Company, where he served as a Partner and Senior Equity Research Analyst covering cell therapy, gene therapy, and gene editing companies. Dr. Prasad succeeds Brendan Smith, who is leaving the Company to pursue external opportunities. "I'm excited to welcome Raju to our leadership team," said Samarth Kulkarni, Ph.D., Chief Exec
-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis- -Durable responses in LBCL achieved with six-month CR rate of 21% and longest response on-going at over 18 months after initial infusion- -Response rates and durability are similar to approved autologous CD19 CAR-T therapies on an ITT basis- -Positively differentiated safety profile; no Grade 3 or higher cytokine release syndrome (CRS) and low rates of infection and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)- -Expanding CARBON into a potentially registrational trial in 1Q 20
-Management to host conference call and webcast on October 12th at 4:30 p.m. ET- ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that management will host a virtual event on October 12, 2021 at 4:30 p.m. ET to highlight clinical data from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies. Conference Call and Web
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)